دورية أكاديمية
أعرض في EDS

Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.

التفاصيل البيبلوغرافية
العنوان: Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.
المؤلفون: Benson JM; Centocor Research & Development, Inc., Division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, Pennsylvania, USA. jbenson4@its.jnj.com, Sachs CW, Treacy G, Zhou H, Pendley CE, Brodmerkel CM, Shankar G, Mascelli MA
المصدر: Nature biotechnology [Nat Biotechnol] 2011 Jul; Vol. 29 (7), pp. 615-24.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature America Publishing Country of Publication: United States NLM ID: 9604648 Publication Model: Print Cited Medium: Internet ISSN: 1546-1696 (Electronic) Linking ISSN: 10870156 NLM ISO Abbreviation: Nat Biotechnol Subsets: MEDLINE
أسماء مطبوعة: Publication: New York Ny : Nature America Publishing
Original Publication: New York, NY : Nature Pub. Co., [1996-
مواضيع طبية MeSH: Antibodies, Monoclonal/*pharmacology , Drug Delivery Systems/*methods , Interleukin-12/*antagonists & inhibitors , Interleukin-23/*antagonists & inhibitors , Signal Transduction/*physiology, Animals ; Antibodies, Monoclonal, Humanized ; Humans ; Signal Transduction/drug effects ; Ustekinumab
مستخلص: Preclinical and clinical studies conducted in the mid-1990s reported strong association and causality between the T-cell helper (T(H)) 1 inductor cytokine interleukin (IL)-12 and numerous immune-mediated disorders, which spurred the development of therapeutic agents targeting IL-12 function. One of the first to enter the clinic, ustekinumab, is a human monoclonal antibody (mAb) that binds to the p40 subunit of IL-12. Subsequent to the generation of ustekinumab, it was discovered that IL-23 also contains the p40 subunit. Thus, although ustekinumab was designed to target IL-12, it also modulates IL-23, a cytokine important to the development and/or maintenance of T(H)17 cells. Clinical observations established that IL-12/23p40 is integral to the pathologies of psoriasis, psoriatic arthritis and Crohn's disease. The molecular and cellular evaluations conducted in ustekinumab clinical programs have provided numerous insights into the pathologic processes of these disorders, illustrating how a novel molecular entity can contribute to our understanding of disease. The individual contributions of these cytokines to specific pathologies require investigation and clinical evaluation of the role of IL-12- and IL-23-specific inhibitors.
References: J Drugs Dermatol. 2010 Jun;9(6):677-83. (PMID: 20645530)
Immunol Res. 2002;25(2):97-113. (PMID: 11999172)
Clin Ther. 2002 Nov;24(11):1720-40; discussion 1719. (PMID: 12501870)
Nat Immunol. 2010 Aug;11(8):674-80. (PMID: 20644573)
Blood. 2005 Dec 1;106(12):3846-53. (PMID: 16081683)
Am J Pathol. 1998 Mar;152(3):667-72. (PMID: 9502407)
N Engl J Med. 2007 Feb 8;356(6):580-92. (PMID: 17287478)
N Engl J Med. 2009 Jul 30;361(5):496-509. (PMID: 19641206)
Nat Rev Immunol. 2003 Feb;3(2):133-46. (PMID: 12563297)
J Exp Med. 1989 Dec 1;170(6):2081-95. (PMID: 2531194)
Eur J Immunol. 2003 Jun;33(6):1461-4. (PMID: 12778462)
Gastroenterology. 1997 Apr;112(4):1169-78. (PMID: 9098000)
J Androl. 1998 May-Jun;19(3):302-7. (PMID: 9639047)
J Am Acad Dermatol. 2007 Dec;57(6):1059-68. (PMID: 17706835)
Blood. 1997 Oct 1;90(7):2541-8. (PMID: 9326219)
Lancet. 2009 Feb 21;373(9664):633-40. (PMID: 19217154)
Int J Clin Pharmacol Ther. 2010 Dec;48(12):830-46. (PMID: 21084039)
Ann Neurol. 1999 Jun;45(6):695-703. (PMID: 10360761)
Nat Immunol. 2007 Sep;8(9):950-7. (PMID: 17676044)
Am J Med. 2009 Dec;122(12):1150.e1-9. (PMID: 19958894)
Immunity. 2010 Aug 27;33(2):192-202. (PMID: 20674401)
J Immunol. 2009 Jul 1;183(1):381-7. (PMID: 19542449)
J Med Genet. 2010 Sep;47(9):635-7. (PMID: 20798129)
J Exp Med. 1995 Jan 1;181(1):381-6. (PMID: 7528773)
Curr Med Res Opin. 2007 May;23(5):1081-92. (PMID: 17519075)
J Immunol. 1998 Sep 15;161(6):3143-9. (PMID: 9743382)
Clin Exp Immunol. 1998 Feb;111(2):377-83. (PMID: 9486407)
Int Immunol. 2009 Feb;21(2):145-53. (PMID: 19088061)
J Immunol. 2001 Jan 1;166(1):642-9. (PMID: 11123348)
J Clin Pharmacol. 2009 Feb;49(2):162-75. (PMID: 19179295)
J Exp Med. 2005 Jan 17;201(2):233-40. (PMID: 15657292)
Curr Opin Infect Dis. 2006 Jun;19(3):245-52. (PMID: 16645485)
Dermatologica. 1978;157(4):238-44. (PMID: 357213)
J Exp Med. 1995 Dec 1;182(6):1985-96. (PMID: 7500044)
Immunity. 2000 Nov;13(5):715-25. (PMID: 11114383)
J Immunol. 1986 Apr 1;136(7):2348-57. (PMID: 2419430)
J Immunol. 2006 Oct 1;177(7):4917-26. (PMID: 16982934)
J Invest Dermatol. 2004 Dec;123(6):1037-44. (PMID: 15610511)
PLoS One. 2011 Feb 22;6(2):e17160. (PMID: 21364948)
J Immunol. 2002 Dec 15;169(12):7104-10. (PMID: 12471147)
J Exp Med. 2002 Jul 1;196(1):129-34. (PMID: 12093877)
Lancet. 2008 May 17;371(9625):1675-84. (PMID: 18486740)
Toxicology. 2003 Apr 1;185(3):221-7. (PMID: 12581697)
Nature. 2003 Feb 13;421(6924):744-8. (PMID: 12610626)
J Exp Med. 1989 Sep 1;170(3):827-45. (PMID: 2504877)
J Biol Chem. 2003 Jan 17;278(3):1910-4. (PMID: 12417590)
Nat Med. 2007 Feb;13(2):139-45. (PMID: 17290272)
J Exp Med. 2003 Dec 15;198(12):1951-7. (PMID: 14662908)
Hum Genet. 2007 Sep;122(2):201-6. (PMID: 17587057)
J Dermatol. 2010 May;37(5):413-25. (PMID: 20536646)
J Invest Dermatol. 1998 Dec;111(6):1053-7. (PMID: 9856816)
Lancet. 2008 May 17;371(9625):1665-74. (PMID: 18486739)
J Clin Pharmacol. 2010 Mar;50(3):257-67. (PMID: 19934030)
Nat Immunol. 2009 Aug;10(8):864-71. (PMID: 19578368)
Clin Immunol. 2007 Jun;123(3):235-43. (PMID: 17329169)
Am J Hum Genet. 2007 Feb;80(2):273-90. (PMID: 17236132)
Nature. 2007 Feb 22;445(7130):866-73. (PMID: 17314973)
Semin Immunol. 2006 Dec;18(6):347-61. (PMID: 16997570)
Nat Biotechnol. 1996 Jul;14(7):845-51. (PMID: 9631008)
Nat Immunol. 2007 Sep;8(9):903-5. (PMID: 17712339)
Birth Defects Res B Dev Reprod Toxicol. 2010 Oct;89(5):351-63. (PMID: 20540088)
J Immunol. 2002 Jun 1;168(11):5699-708. (PMID: 12023369)
Drug Discov Today. 2009 Sep;14(17-18):891-8. (PMID: 19520183)
Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14002-7. (PMID: 8943050)
Immunity. 2009 May;30(5):646-55. (PMID: 19464987)
J Immunol. 1999 Jun 15;162(12):7480-91. (PMID: 10358203)
J Clin Pharmacol. 2006 Nov;46(11):1268-89. (PMID: 17050792)
Neurology. 1998 Sep;51(3):753-8. (PMID: 9748022)
Nat Immunol. 2007 Sep;8(9):942-9. (PMID: 17676045)
Clin Cancer Res. 1999 Dec;5(12):3983-9. (PMID: 10632329)
J Mol Biol. 2010 Oct 8;402(5):797-812. (PMID: 20691190)
Lancet Neurol. 2008 Sep;7(9):796-804. (PMID: 18703004)
Cytokine Growth Factor Rev. 2004 Oct;15(5):367-77. (PMID: 15450252)
N Engl J Med. 2010 Jan 14;362(2):118-28. (PMID: 20071701)
J Neuroimmunol. 1996 Oct;70(1):87-90. (PMID: 8862139)
Gastroenterology. 2008 Oct;135(4):1130-41. (PMID: 18706417)
Science. 2006 Dec 1;314(5804):1461-3. (PMID: 17068223)
Curr Med Res Opin. 2006 Sep;22(9):1671-8. (PMID: 16968570)
Clin Pharmacol Ther. 2008 Nov;84(5):548-58. (PMID: 18784655)
المشرفين على المادة: 0 (Antibodies, Monoclonal)
0 (Antibodies, Monoclonal, Humanized)
0 (Interleukin-23)
187348-17-0 (Interleukin-12)
FU77B4U5Z0 (Ustekinumab)
تواريخ الأحداث: Date Created: 20110713 Date Completed: 20120302 Latest Revision: 20211020
رمز التحديث: 20221213
DOI: 10.1038/nbt.1903
PMID: 21747388
قاعدة البيانات: MEDLINE
الوصف
تدمد:1546-1696
DOI:10.1038/nbt.1903